Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.
| Disease | Cell Type | Therapeutic or Technology | Institution | Stage | Project Objective | Details |
|---|---|---|---|---|---|---|
| Heart Disease, Hypertension, pulmonary arterial, Pulmonary Hypertension | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCLA |  |
Pre-IND/IDE or Equivalent | |
| Neurological Disorders, Spinal Cord Injury | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | UC Irvine | |
Pre-IND/IDE or Equivalent | |
| Duchenne Muscular Dystrophy, Skeletal/Smooth Muscle disorders | Somatic Cell | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | MyoGene Bio LLC | |
Pre-IND/IDE or Equivalent | |
| Genetic Disorder, Metabolic Disorders | Somatic Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Immusoft Corporation | |
Pre-IND/IDE or Equivalent | |
| Blood Disorders, IPEX Syndrome | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | ImmunoVec | |
Pre-IND/IDE or Equivalent | |
| Neurological Disorders, Stroke | iPS Cell | Donor cell therapy, Therapeutic Approach | PAVIR | |
Pre-IND/IDE or Equivalent | |
| Cancer, Melanoma, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCLA | |
Pre-IND/IDE or Equivalent | |
| Blood Cancer, Cancer, Multiple Myeloma | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | UCLA | |
Pre-IND/IDE or Equivalent | |
| Brain Injury, hypoxic, ischemic, Neurological Disorders, Pediatrics | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Sanford-Burnham | |
Pre-IND/IDE or Equivalent | |
| Neurological Disorders, Traumatic Brain Injury | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | UC Irvine | |
Pre-IND/IDE or Equivalent | |
| Blood Disorders, Hyper IgM Syndrome, Immune Disease | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCLA | |
Pre-IND/IDE or Equivalent | |
| Age-related macular degeneration, Vision Loss | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Stanford | |
Pre-IND/IDE or Equivalent | |
| Bladder or Urinary Tract Disorder, Incontinence, Skeletal/Smooth Muscle disorders | iPS Cell | Personalized cell therapy, Therapeutic Approach | Stanford | |
Pre-IND/IDE or Equivalent | |
| Intestinal Disease, Metabolic Disorders, Neurological Disorders, Pediatrics | iPS Cell | Donor cell therapy, Therapeutic Approach | CHLA | |
Pre-IND/IDE or Equivalent | |
| Epilepsy, Neurological Disorders | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Neurona Therapeutics |  |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Blood Disorders, Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCSF |  |
Clinical Trial, Phase 3 | |
| Ray Therapeutics, INC | ||||||
| Heart Disease, Heart failure | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Tenaya Therapeutics, Inc. | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Blood Disorders, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) | Adult or Tissue Stem Cell | Biologic, Gene modification, Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCLA | |
Clinical Trial, Phase 3 | |
| Immune Disease | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Tr1X Inc. | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Autoimmune Disorder, Lupus, Systemic Lupus Erythematosus (SLE) | iPS Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Fate Therapeutics | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) | Somatic Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Senti Bio | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Blood Disorders | Somatic Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Nexcella, Inc. | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Neurological Disorders, Parkinson's Disease | iPS Cell | Personalized cell therapy, Therapeutic Approach | Aspen Neuroscience | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Brain Cancer, Cancer, Solid Tumors | Somatic Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | UCSF | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Cancer, Solid Tumors | Somatic Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Allogene Therapeutics | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Brain Cancer, Cancer, Solid Tumors | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | UCSF | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Age-related macular degeneration, Vision Loss | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | Luxa Biotechnology | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Danon Disease, Metabolic Disorders, Pediatrics | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Rocket Pharmaceuticals, Inc. | |
Clinical Trial, Phase 2 | ||
| Brain Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Developmental Disorders, Neurological Disorders, Spina Bifida | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | UC Davis | |
Clinical Trial, Phase 2 | |
| Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | COH | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Neurological Disorders, Other | Gene Therapy (All), Gene Therapy, cell free, Nucleic acid based therapy, Therapeutic Approach | UCSD | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Cancer, Melanoma, Solid Tumors | Somatic Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Kidney Disease | Adult or Tissue Stem Cell | Donor cell therapy, Therapeutic Approach | UCLA | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Age-related macular degeneration, Vision Loss | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Regenerative Patch Technologies LLC | |
Clinical Trial, Phase 2 | |
| HIV/AIDS, Infectious Disease | Other | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | COH | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Neurological Disorders, Vision Loss | Somatic Cell | Personalized cell therapy, Therapeutic Approach | Immusoft Corporation | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Corneal Damage, Vision Loss | Adult or Tissue Stem Cell | Biologic, Exosomes based therapy, Therapeutic Approach | Combangio | |
Clinical Trial, Phase 2 | |
| Cancer, Solid Tumors | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Eureka Therapeutics, Inc. | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| B cell cancers, Blood Cancer, Cancer | Somatic Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | Angiocrine |  |
Clinical Trial, Phase 3 | |
| Anemia, Blood Disorders | Adult or Tissue Stem Cell | Antibody, Biologic, Therapeutic Approach | Stanford | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Bone or Cartilage Disease, Osteoarthritis | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Genascence Corporation | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Anemia, Blood Disorders, Bone Marrow Transplant and Viral Infection | Adult or Tissue Stem Cell | Immune tolerance/management, Technology | Stanford | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Anemia, Blood Disorders | Somatic Cell | Cell processing & handling, Immune tolerance/management, Technology | COH | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Epilepsy, Neurological Disorders | Embryonic Stem Cell | Donor cell therapy, Therapeutic Approach | Neurona Therapeutics | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| HIV/AIDS, Infectious Disease | Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach | Excision BioTherapeutics | |
Clinical Trial, Phase 1 or Phase 1/2 | ||
| Blood Disorders, IPEX Syndrome | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach | Stanford | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Brain Cancer, Cancer, Solid Tumors | Adult or Tissue Stem Cell | Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach | COH | |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Cancer, Solid Tumors | Adult or Tissue Stem Cell | Personalized cell therapy, Therapeutic Approach | BioEclipse Therapeutics INC. | |
Clinical Trial, Phase 1 or Phase 1/2 |
